Lee A
School of Microbiology and Immunology, University of New South Wales, Kensington, Sydney, Australia.
Baillieres Clin Gastroenterol. 1995 Sep;9(3):615-32. doi: 10.1016/0950-3528(95)90051-9.
Following the demonstration of Helicobacter pylori as a major gastroduodenal pathogen there was a need to develop animal models in order to investigate mechanisms of pathogenesis and to be able to test new treatment strategies. Helicobacter pylori will only colonize a limited number of hosts including non-human primates, germ-free or barrier raised piglets, germ-free dogs and recently laboratory raised cats. Although these models have proved useful there is a need for more convenient small animal models. The ferret infected with its natural gastric organism, Helicobacter mustelae, is the only other animal to show peptic ulceration and has been successfully used to investigate gastritis and antimicrobial agents. The other commonly used animal model is the laboratory mouse or rat infected with either Helicobacter felis or Helicobacter heilmannii, bacteria that normally colonize cat or dog gastric mucosae. Active/chronic gastritis, gastric atrophy, and lymphoma-like lesions have been shown to develop in H. felis infected mice. The most recent and exciting use of an animal model has been the use of the H. felis mouse model in the development of human vaccines against H. pylori. Mice can be protected against infection with large doses of viable H. felis by oral immunization using sonicates of H. felis or H. pylori or recombinant H. pylori urease together with cholera toxin or cholera toxin-B subunit as the mucosal adjuvant. More importantly it has been shown that immunization of already infected animals results in eradication of infection. This raises the intriguing possibility that therapeutic immunization might be a viable option in the management of Helicobacter-associated disease. If immunization as a therapy of peptic ulcers was combined with short-term acid suppression, the possibility of reinfection may also be eliminated. In those countries where H. pylori infection rates are very high and infection occurs at an early age, large scale oral immunization of sections of the community would not only protect the young from the deleterious consequences of long-term H. pylori infection but could also cure existing disease.
在证实幽门螺杆菌是主要的胃十二指肠病原体之后,有必要开发动物模型,以便研究发病机制并能够测试新的治疗策略。幽门螺杆菌仅能在有限数量的宿主中定殖,包括非人灵长类动物、无菌或屏障饲养的仔猪、无菌犬以及最近实验室饲养的猫。尽管这些模型已被证明有用,但仍需要更方便的小动物模型。感染其自然胃部病原体——鼬獾幽门螺杆菌的雪貂,是唯一另一种出现消化性溃疡的动物,并已成功用于研究胃炎和抗菌剂。另一种常用的动物模型是感染了猫幽门螺杆菌或海尔曼幽门螺杆菌的实验室小鼠或大鼠,这两种细菌通常定殖于猫或犬的胃黏膜。已证明感染猫幽门螺杆菌的小鼠会出现活动性/慢性胃炎、胃萎缩和淋巴瘤样病变。动物模型最近最令人兴奋的用途是在开发针对幽门螺杆菌的人类疫苗中使用猫幽门螺杆菌小鼠模型。通过使用猫幽门螺杆菌或幽门螺杆菌的超声裂解物或重组幽门螺杆菌脲酶,以及霍乱毒素或霍乱毒素B亚基作为黏膜佐剂进行口服免疫,可以保护小鼠免受大剂量活猫幽门螺杆菌的感染。更重要的是,已证明对已感染动物进行免疫会导致感染的根除。这就提出了一个有趣的可能性,即治疗性免疫可能是管理幽门螺杆菌相关疾病的一个可行选择。如果将免疫作为消化性溃疡的一种治疗方法与短期抑酸相结合,再感染的可能性也可能被消除。在幽门螺杆菌感染率非常高且感染发生在幼年的国家,对部分社区进行大规模口服免疫不仅可以保护年轻人免受长期幽门螺杆菌感染的有害后果,还可以治愈现有疾病。